Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) Director William Aliski sold 6,000 shares of the firm’s stock in a transaction dated Thursday, November 8th. The shares were sold at an average price of $55.67, for a total value of $334,020.00. Following the completion of the transaction, the director now directly owns 72,610 shares in the company, valued at $4,042,198.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

William Aliski also recently made the following trade(s):

  • On Monday, October 8th, William Aliski sold 19,550 shares of Ultragenyx Pharmaceutical stock. The shares were sold at an average price of $72.49, for a total value of $1,417,179.50.

Shares of NASDAQ RARE opened at $52.24 on Friday. Ultragenyx Pharmaceutical Inc has a 1 year low of $41.67 and a 1 year high of $90.98. The stock has a market cap of $2.73 billion, a PE ratio of -6.97 and a beta of 2.34.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Monday, November 5th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.94) by $0.20. Ultragenyx Pharmaceutical had a negative return on equity of 41.08% and a negative net margin of 508.70%. The business had revenue of $11.80 million for the quarter, compared to analyst estimates of $11.97 million. During the same period in the previous year, the company earned ($1.87) earnings per share. The company’s revenue for the quarter was up 5800.0% compared to the same quarter last year. As a group, research analysts predict that Ultragenyx Pharmaceutical Inc will post -4.09 EPS for the current year.

Several research firms have commented on RARE. Credit Suisse Group cut their price objective on Ultragenyx Pharmaceutical from $78.00 to $59.00 and set a “hold” rating on the stock in a research report on Monday, October 29th. Wedbush raised their price objective on Ultragenyx Pharmaceutical from $71.00 to $80.00 and gave the company an “outperform” rating in a research report on Monday, August 6th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, August 29th. Raymond James raised their price objective on Ultragenyx Pharmaceutical from $53.00 to $57.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, Canaccord Genuity cut their price objective on Ultragenyx Pharmaceutical from $90.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and fifteen have given a buy rating to the company. Ultragenyx Pharmaceutical currently has a consensus rating of “Buy” and an average target price of $75.95.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. increased its position in shares of Ultragenyx Pharmaceutical by 3.8% during the second quarter. BlackRock Inc. now owns 4,389,350 shares of the biopharmaceutical company’s stock worth $337,408,000 after acquiring an additional 158,723 shares during the last quarter. Federated Investors Inc. PA increased its position in shares of Ultragenyx Pharmaceutical by 18.2% during the second quarter. Federated Investors Inc. PA now owns 1,417,551 shares of the biopharmaceutical company’s stock worth $108,967,000 after acquiring an additional 218,060 shares during the last quarter. First Trust Advisors LP increased its position in shares of Ultragenyx Pharmaceutical by 29.3% during the third quarter. First Trust Advisors LP now owns 1,263,466 shares of the biopharmaceutical company’s stock worth $96,453,000 after acquiring an additional 285,961 shares during the last quarter. Alliancebernstein L.P. grew its stake in Ultragenyx Pharmaceutical by 5.4% in the third quarter. Alliancebernstein L.P. now owns 992,357 shares of the biopharmaceutical company’s stock worth $75,757,000 after purchasing an additional 50,489 shares in the last quarter. Finally, Northern Trust Corp grew its stake in Ultragenyx Pharmaceutical by 6.7% in the second quarter. Northern Trust Corp now owns 554,092 shares of the biopharmaceutical company’s stock worth $42,594,000 after purchasing an additional 34,942 shares in the last quarter. 96.78% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “William Aliski Sells 6,000 Shares of Ultragenyx Pharmaceutical Inc (RARE) Stock” was first posted by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.dailypolitical.com/2018/11/10/william-aliski-sells-6000-shares-of-ultragenyx-pharmaceutical-inc-rare-stock.html.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.

See Also: Intrinsic Value

Insider Buying and Selling by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.